🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

RecruitingPhase 3Ages 18 Years - anyAllPfizer
NCT07792954 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and parti

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant recent weight change (\>5% within 3 months). * Type 1 diabetes mellitus. * History of pancreatitis. * Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2). * Recent bariatric surgery or obesity procedures. * Pregnancy or breastfeeding.
💊

What it tests

  • Berobenatide
  • Placebo
📍

Where

34 sites
The Second People's Hospital of Hefei
Hefei, China
Peking University People's Hospital
Beijing, China
Beijing Friendship Hospital
Beijing, China
Beijing Pinggu Hospital
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China
Chongqing People's Hospital
Chongqing, China
Chongqing University Three Gorges Hospital
Chongqing, China
Huizhou Central People's Hospital
Huizhou, China

…and 26 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy